A Financial Analysis and Valuation of Pfizer

Yutong Wei

doi:10.54254/2754-1169/122/20242488

Research Article

Open access

Published on 25 October 2024

Download pdf

Wei,Y. (2024). A Financial Analysis and Valuation of Pfizer. Advances in Economics, Management and Political Sciences,122,59-65.

Export citation

A Financial Analysis and Valuation of Pfizer

Yutong Wei *^,1,

¹ Finance School, Tianjin University of Finance and Economics, Tianjin, 300221, China

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2754-1169/122/20242488

Abstract

The rational valuation of the healthcare industry and the analysis and research of the financial risks faced by enterprises can not only provide a basis for rational investment and transaction pricing decisions, but also help enterprises to find out the shortcomings of the production and operation, so as to improve the management mode of the enterprise, and help enterprises to achieve the maximisation of management. Firstly, this paper analyse the risks faced by Pfizer from a financial point of view by quantitatively comparing the data of Pfizer and its two competitors, Amgen and Unitedhealth Group, and then qualitatively analysing their characteristics in terms of liquidity, solvency and profitability and the reasons for this. Next, Pfizer is valued by looking at its leverage, business risk, earnings per share, etc. to measure the financial risk of the business and the reasons for the capital structure. It then gives investors an objective investment recommendation by forecasting Pfizer's future share price. The study concludes that Pfizer Inc. is illiquid, has poor corporate solvency, is at risk of debt servicing, and has suffered a significant decline in profitability. Valuing Pfizer, the forecast suggests that Pfizer's stock is currently undervalued.

Keywords

Company Valuation, Liquidity, Solvency, Profitability, Business Risk.

View pdf

References

[1]. Lakdawalla, D. N. (2018). Economics of the pharmaceutical industry. Journal of Economic Literature, 56(2), 397-449.

[2]. Hatton, R. C., Leighton, G., & Englander, L. (2022). Countries manufacturing pharmaceuticals for the US market: a 10-year analysis of public data. Annals of Pharmacotherapy, 56(10), 1106-1112.

[3]. Alkhyeli, S., Abdulla, F., Alshehhi, A., Aldhaheri, N., Alhosani, M., Alsereidi, A., & Nobanee, H. (2021). Financial analysis and performance evaluation of Pfizer. Available at SSRN 3896385.

[4]. PFIZER INC. (2023). 2023 Annual Report. Retrieved from https://annualreport.stocklight.com/nyse/Pfe/23658781.pdf

[5]. Gao, J., & Zhang, Y. (2023). Assessing the Financial Stability & Investment Potential of Pfizer Inc. Highlights in Business, Economics and Management, 15, 27-32.

[6]. Jackson, A. B. (2022). Financial statement analysis: a review and current issues. China Finance Review International, 12(1), 1-19.

[7]. Zhang, J., Haselkorn, M., & Ahmed, S. U. (2009). Financial analysis of global pharmaceutical companies for 2006 and 2007. International Journal of Organizational Innovation (Online), 1(3), 19.

[8]. Palepu, K. G., Healy, P. M., Wright, S., Bradbury, M., & Coulton, J. (2020). Business analysis and valuation: Using financial statements. Cengage AU.

[9]. Fleming, C. E. (2019). Historical Study of United Healthcare’s Communication Themes from 2010 to 2015, Grand Canyon University.

[10]. Okafor, A., Adeleye, B. N., & Adusei, M. (2021). Corporate social responsibility and financial performance: Evidence from US tech firms. Journal of cleaner production, 292, 126078.

[11]. South, B. J. (2023). Business adaptive strategies in crisis: the case of Pfizer’s COVID-19 vaccine, Portuguese Catholic University.

Cite this article

Wei,Y. (2024). A Financial Analysis and Valuation of Pfizer. Advances in Economics, Management and Political Sciences,122,59-65.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 8th International Conference on Economic Management and Green Development

Conference website: https://2024.icemgd.org/

ISBN：978-1-83558-667-9(Print) / 978-1-83558-668-6(Online)

Conference date: 26 December 2024

Editor：Lukáš Vartiak

Series: Advances in Economics, Management and Political Sciences

Volume number: Vol.122

ISSN：2754-1169(Print) / 2754-1177(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).